A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin

Calcified Tissue International

Volumn 59, Issue 1, 1996, Pages 12-16

  Overgaard, K ^a   Christiansen, C ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

Biochemical markers; Bone mineral content; Bone turnover; Calcitonin; Intermittent therapy

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; CALCIUM; CREATININE; OSTEOCALCIN; PYRIDONE DERIVATIVE; SALCATONIN;

AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CALCIUM INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; HUMAN; INTRANASAL DRUG ADMINISTRATION; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINE RADIOGRAPHY; URINE LEVEL; VERTEBRA FRACTURE;

ADMINISTRATION, INTRANASAL; AGED; AMINO ACIDS; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; CALCITONIN; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS;

EID: 0030018531     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002239900077     Document Type: Article

References (26)

1. Hedlund T, Hulth A, Johnell O (1983) Early effects of parathormone and calcitonin on the number of osteoclasts and on serum-calcium in rats. Acta Orthop Scand 54:802-804
2. Overgaard K, Riis BJ, Christiansen C, Pødenphant J, Johansen JS (1989) Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 30:435-442
3. Overgaard K, Hansen MA, Jensen SB, Christiansen C (1992) Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis. A dose-response study. Br Med J 305:556-561
4. Farley JR, Hall SL, Herring S, Tarbaux NM (1992) Two biochemical indices of mouse bone formation are increased, in vivo, in response to calcitonin. Calcif Tissue Int 50:67-73
5. Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesnut CH III (1984) Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33:295-303
6. Overgaard K, Agnusdei D, Hansen MA, Maioli E, Christiansen C, Gennari C (1991) Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 72:344-349
7. Fleisch H (1991) Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42:919-944
8. Gennari C, Chierichetti SM, Bigazzi S, Fusi L, Gonnelli S, Ferrara R, Zacchei F (1985) Comparative effects of bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 38:455-464
9. Bouizar Z, Rostene WH, Milhaud G (1987) Down-regulation of rat kidney calcitonin receptors by salmon calcitonin infusion evidenced by autoradiography. Proc Natl Acad Sci USA 84:5125-5128
10. Reginster JY, Denis D, Albert A, Deroisy R, Lecart MP, Fontaine MA, Lambelin P, Franchimont P (1987) 1-year controlled randomized trial of prevention of early postmenopausal bone loss by intranasal calcilonin. Lancet ii:1481-1483
11. Overgaard K, Hansen MA, Herss Nielsen V-A, Riis BJ, Christiansen C (1990) Discontinuous calcitonin treatment of established osteoporosis - effects of withdrawal of treatment. Am J Med 89:1-6
12. Gennari C, Agnusdei D, Cepollaro C, Zacchei F, Camporeale A, Montagnani M (1992) Effect on bone mass and bone turnover of a 2-year intermittent or continuous treatment with salmon calcitonin nasal spray in postmenopausal osteoporotic patients. In: Cohn DV, Gennari C, Tashjian AH (eds) Calcium regulating hormones and bone metabolism. Elsevier Science Publishers, Netherlands, pp 400-406
13. Schlemmer A, Johansen JS, Pedersen SA, Jørgensen JOL, Hassager C, Christiansen C (1991) The effect of growth hormone (GH) therapy on urinary pyridinoline cross-links in GH-deficient adults. Clin Endocrinol 35:471-476
14. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C (1994) Evaluation of an immunoassay (CrossLaps™ ELISA) for quantitation of type I collagen degradation products in urine. Clin Chem 40:2022-2025
15. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C (1995) Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps). Follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 80:864-868
16. The Committee on Enzymes of the Scandinavian Society for Clinical Chemistry and Clinical Physiology: Recommended methods for the determination of four enzymes in blood (1974) Scand J Clin Lab Invest 33:291-306
17. Johansen JS, Mølholm Hansen JE, Christiansen C (1987) A radioimmunoassay for bone Gla protein (BGP) in human plasma. Acta Endocrinol 114:410-416
18. Pødenphant J, Larsen N-E, Christiansen C (1984) An easy and reliable method for determination of urinary hydroxyproline. Clin Chim Acta 142:145-148
19. Melton III LJ (1988) Epidemiology of fractures. In: Riggs BL, Melton III LJ (eds). Osteoporosis. Etiology, diagnosis, and management. New York: Raven Press, pp 133-154
20. Matthews JNS, Altman DG, Campbell MJ, Royston P (1990) Analysis of serial measurements in medical research. Br Med J 300:230-235
21. Peck WA, Christiansen C, Fleisch HA, Genant HK, Gennari C, Martin TJ et al. (1993) Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94:646-650
22. Jordan A, Dutta S, Lutwak L, Troendle G, Sobel S (1993) Draft Version of FDA-Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Division of Metabolism and Endocrine Drug Products Food and Drug Administration 1-19
23. Nilas L, Pødenphant J, Riis BJ, Gotfredsen A, Christiansen C (1987) Usefulness of regional bone measurements in patients with osteoporotic fractures of the spine and distal forearm. J Nucl Med 28:960-965
24. Christiansen C, Riis BJ (1990) 17β-Estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 71:836-841
25. Munk Nielsen N, von der Recke P, Hansen MA, Overgaard K, Christiansen C (1994) Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers. Calcif Tissue Int 55:8-11
26. Riis BJ, Overgaard K, Christiansen C (1995) Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy. Osteoporosis Int 5:276-280